Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2016 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.00001
Symbol
PTGX on Nasdaq
Shares outstanding
62,162,717
Price per share
$87.34
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
70,682,882
Total reported value
$4,695,305,157
% of total 13F portfolios
0.01%
Share change
-293,723
Value change
+$3,939,450
Number of holders
272
Price from insider filings
$87.34
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 14% -6.7% $569,681,692 -$33,813,734 8,575,669 -5.6% BlackRock, Inc. 30 Sep 2025
Farallon Capital Partners, L.P. 10% $265,004,151 5,956,488 Dapice Joshua J. 31 Dec 2024
STATE STREET CORP 5.2% +20% $170,012,022 +$26,561,215 3,207,774 +19% STATE STREET CORPORATION 30 Jun 2025
BIOTECHNOLOGY VALUE FUND L P 4.1% -22% $170,121,650 -$43,187,804 2,560,916 -20% BVF PARTNERS L P/IL 30 Sep 2025
Deep Track Capital, LP 2.8% -51% $113,973,353 -$101,924,147 1,715,691 -47% Deep Track Capital, LP 30 Sep 2025

As of 30 Sep 2025, 272 institutional investors reported holding 70,682,882 shares of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX). This represents 114% of the company’s total 62,162,717 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) together control 88% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 15% 9,404,232 -2.3% 0.01% $624,723,149
FARALLON CAPITAL MANAGEMENT LLC 10% 6,196,006 +0.39% 2.3% $411,600,679
RTW INVESTMENTS, LP 9.3% 5,756,277 0% 4.7% $382,389,481
VANGUARD GROUP INC 6.8% 4,257,229 -2.3% 0% $282,807,724
STATE STREET CORP 5.1% 3,165,795 -1.3% 0.01% $210,303,762
BVF INC/IL 4.1% 2,560,916 -20% 6.9% $170,121,650
JOHNSON & JOHNSON 3.9% 2,449,183 0% 32% $162,699,227
WELLINGTON MANAGEMENT GROUP LLP 3.1% 1,908,446 +84% 0.02% $126,778,068
UBS Group AG 3.1% 1,896,008 -24% 0.02% $125,951,812
Deep Track Capital, LP 2.8% 1,715,691 -47% 3.2% $113,973,353
Woodline Partners LP 2.3% 1,438,247 +52% 0.45% $95,542,748
GEODE CAPITAL MANAGEMENT, LLC 2.3% 1,416,646 -1.9% 0.01% $94,122,036
PRICE T ROWE ASSOCIATES INC /MD/ 2% 1,220,436 +30% 0.01% $81,075,000
Driehaus Capital Management LLC 1.8% 1,139,854 +50% 0.54% $75,720,501
JANUS HENDERSON GROUP PLC 1.8% 1,100,821 +146% 0.03% $73,165,449
MARSHALL WACE, LLP 1.7% 1,085,564 0.08% $72,114,017
PERCEPTIVE ADVISORS LLC 1.7% 1,030,134 -4.1% 2% $68,431,802
Commodore Capital LP 1.6% 1,025,000 -4.7% 3.3% $68,090,750
Invesco Ltd. 1.6% 1,003,706 +39% 0.01% $66,676,188
ADAR1 Capital Management, LLC 1.6% 989,182 +4.3% 6.6% $65,711,360
BANK OF AMERICA CORP /DE/ 1.3% 829,877 -2.6% 0% $55,128,729
Pictet Asset Management Holding SA 1.3% 822,212 +9.3% 0.05% $54,619,543
Jefferies Financial Group Inc. 1.3% 821,503 -0.31% 0.5% $54,572,444
GOLDMAN SACHS GROUP INC 1.3% 781,711 +0.57% 0.01% $51,929,062
MORGAN STANLEY 1.2% 768,358 -12% 0% $51,042,046

Institutional Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 96,309 $8,392,941 -$5,657,924 $87.34 15
2025 Q3 70,682,882 $4,695,305,157 +$3,939,450 $66.43 272
2025 Q2 70,977,321 $3,923,985,934 +$344,775,786 $55.27 273
2025 Q1 64,994,031 $3,143,069,159 +$116,416,679 $48.36 273
2024 Q4 63,271,382 $2,442,272,169 +$44,242,054 $38.60 240
2024 Q3 61,602,509 $2,772,507,649 -$40,480,651 $45.00 238
2024 Q2 59,068,539 $2,046,920,014 -$15,105,959 $34.65 187
2024 Q1 59,715,204 $1,727,559,912 +$80,356,864 $28.93 183
2023 Q4 57,464,862 $1,317,641,644 +$12,220,647 $22.93 155
2023 Q3 56,712,373 $945,896,121 -$53,252,231 $16.68 142
2023 Q2 56,731,936 $1,566,841,397 +$104,873,016 $27.62 163
2023 Q1 53,194,090 $1,222,410,149 +$179,899,701 $23.00 135
2022 Q4 49,023,797 $534,831,663 +$12,387,471 $10.91 135
2022 Q3 47,348,207 $399,128,639 -$50,141,212 $8.43 129
2022 Q2 53,360,764 $422,090,018 -$73,694,821 $7.91 125
2022 Q1 50,329,296 $1,191,811,689 -$6,168,618 $23.68 136
2021 Q4 49,204,800 $1,682,561,970 +$93,460,895 $34.20 144
2021 Q3 46,239,107 $819,492,437 -$246,905,195 $17.72 126
2021 Q2 47,991,061 $2,154,082,054 +$179,883,058 $44.88 136
2021 Q1 44,189,630 $1,144,564,352 +$27,791,318 $25.90 124
2020 Q4 43,016,906 $867,295,836 +$98,827,896 $20.16 124
2020 Q3 37,171,432 $727,253,818 +$62,067,302 $19.55 91
2020 Q2 34,047,384 $601,265,429 +$210,058,150 $17.66 82
2020 Q1 23,373,035 $165,030,731 +$1,225,355 $7.06 75
2019 Q4 23,195,067 $163,521,727 +$7,867,560 $7.05 79
2019 Q3 18,937,325 $227,502,940 +$20,583,092 $12.01 74
2019 Q2 17,221,305 $208,468,560 +$25,952,329 $12.11 66
2019 Q1 15,062,271 $189,318,050 +$21,734,111 $12.57 64
2018 Q4 13,856,660 $93,215,143 -$9,989,308 $6.73 62
2018 Q3 16,027,640 $164,867,528 +$26,771,021 $10.29 60
2018 Q2 13,927,964 $93,611,738 +$10,872,610 $6.72 68
2018 Q1 11,933,401 $102,508,360 -$12,039,057 $8.59 67
2017 Q4 11,834,743 $246,147,238 +$77,189,243 $20.80 64
2017 Q3 8,125,676 $143,579,627 +$619,413 $17.67 41
2017 Q2 8,119,093 $91,824,177 -$276,502 $11.31 40
2017 Q1 8,008,863 $102,590,269 +$4,468,821 $12.81 39
2016 Q4 7,976,789 $174,812,982 +$2,372,202 $21.99 38
2016 Q3 6,904,061 $144,850,726 +$144,850,726 $21.13 34